The practicalities and ethics of ketamine for depression

The Lancet Psychiatry

Volumn 4, Issue 5, 2017, Pages 354-355

  Ryan, Christopher James ^a   Loo, Colleen ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHICS; HUMAN; NOTE; PRIORITY JOURNAL; TACHYPHYLAXIS; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

DEPRESSION; DEPRESSIVE DISORDER; HUMANS; KETAMINE;

EID: 85017093064     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30155-4     Document Type: Note

References (9)

1. 1 Singh, I, Morgan, C, Curran, V, Nutt, D, Schlag, A, McShane, R, Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry, 2017 http://dx.doi.org/10.1016/S2215-0366(17)30102-5 published online April 5.
2. 2 Xu, Y, Hackett, M, Carter, G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 19, 2016, pyv124.
3. 3 Gálvez, V, O'Keefe, E, Cotiga, L, et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. Biol Psychiatry 76 (2014), e1–e2.
4. 4 Bonnet, U, Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction. J Psychoactive Drugs 47 (2015), 276–285.
5. 5 Singh, JB, Fedgchin, M, Daly, EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173 (2016), 816–826.
6. 6 Zhang, MW, Ho, RC, Ethical considerations for clinical research and off-label use of ketamine to treat mood disorders: the balance between risks and benefits. Ethics Behav, 2016, 10.1371/journal.pone.0173202 published online May 17.
7. 7 Loo, C, Is ketamine ready to be used clinically for the treatment of depression?. Med J Australia, 203, 2015, 425.
8. 8 Sisti, D, Segal, AG, Thase, ME, Proceed with caution: off-label ketamine treatment for major depressive disorder. Curr Psychiatry Rep, 16, 2014, 527.
9. 9 Malhi, GS, Lingford-Hughes, AR, Young, AH, Antidepressant treatment response: ‘I want it all, and I want it now!’. Br J Psychiat 208 (2016), 101–103.